IMUGENE CHART. TA only, page-32934

FID,

The first ph1 trial for Renovo/Vaxinia using the TAMP technology is planned for next year. Reon kindly pointed this out a few days ago. It is buried in the Bell Potter presentation . It’s probably for Pancreatic Cancer.

Mr Witt would be referring to the results of the animal studies they have done but not released the results of. It’s almost definitely the case that an application to run the ph1 trials . Once the FDA has approved the trial , IMU will make the announcement to the market.

This is the usual course of events. But LC did flag it when she sneakily slipped it into the presentation. That’s why I find it pays to listen very carefully to every word she says . She can’t help herself she loves giving little clues to the future moves.

After very close. Examination of that presentation, it certainly gave the impression that the forward planning strongly supports the verbal claims she makes about “data unlike anything anywhere else in the world”. “The best results I’ve ever seen from a ph1 trial” etc.

There isn’t any doubts in my mind this company is going to be a superstar. I know I’ve ignored Slicks advice from yesterday to wait for the signal of a turnaround here, but I have been buying again. Because my read of the charts is that this is just waiting for an announcement to to send IMU back up again. Last time it rapidly ran from .04 to .15. I want to be well and truly loaded up because the next run will be much bigger .

The weight of evidence that CF33 /Oncarlytics/Azer-Cel therapies are paradigm shifting is getting hard to ignore.